ArticleInternational journal of surgery case reports2026
Sustained functional recovery one year after TFCC debridement with adjuvant umbilical cord-mesenchymal stem cells and secretome therapy: a case report.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and Importance: Triangular fibrocartilage complex (TFCC) tears can significantly impair wrist stability and daily function. Regenerative medicine, particularly mesenchymal stem cell-based therapy, may complement traditional surgical approaches such as debridement with synovectomy to enhance recovery. Presentation of Case: This report presents the 1-year follow-up of a 41-year-old male with a TFCC tear previously treated with debridement synovectomy followed by intra-articular umbilical cord-derived mesenchymal stem cells (UC-MSCs) and UC-MSC-derived secretome. UC-MSCs were selected for their regenerative potential and well-established roles in tissue repair. Clinical evaluations were performed pretreatment, at 6 months, and at 12 months. Outcomes were assessed using magnetic resonance imaging (MRI), the Visual Analogue Scale (VAS), and the Disabilities of the Arm, Shoulder and Hand (DASH) score. At 12 months, the patient maintained a VAS score of 0, indicating complete and sustained pain resolution. Functional improvement continued, with the DASH score progressing from 12 at 6 months to 5.8 at 12 months. MRI findings demonstrated stable postoperative healing without recurrent injury or degenerative change. Clinical Discussion: One-year follow-up shows near-complete restoration of daily wrist function. No adverse events related to UC-MSC or secretome administration occurred. These results suggest that UC-MSC-based therapy may provide durable regenerative benefits when used as an adjuvant to debridement with synovectomy. Conclusion: One year after surgery supplemented with UC-MSC and secretome therapy, the patient demonstrates sustained pain relief and progressive functional recovery. This case supports the potential role of UC-MSC-based therapy in enhancing long-term outcomes in TFCC injury, warranting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.